NCT03688269View on ClinicalTrials.gov

Minimal Effective Concentration (EC90) of Ropivacaine

PHASE3CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

October 5, 2018

Primary Completion Date

November 4, 2019

Study Completion Date

May 4, 2020

Conditions
Anesthesia, ConductionRopivacaineDexamethasoneAxillary Brachial Plexus Block
Interventions
DRUG

Intravenous dexamethasone

Intravenous injection of 8mg/2ml dexamethasone

DRUG

Intravenous saline

Intravenous injection of 2ml Saline 0.9%

DRUG

Perineural ropivacaine

Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method

Trial Locations (1)

25030

Centre Hospitalier Universitaire de Besançon, Besançon

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT03688269 - Minimal Effective Concentration (EC90) of Ropivacaine | Biotech Hunter | Biotech Hunter